Boris Kuvshinoff II, MD, MBA
Areas of Expertise:
Neuroendocrine tumors - Carcinoid, Islet cell tumors of pancreas
Gallbladder and bile duct cancer
I am the Co-Director of the Hepato-Pancreato-Biliary (HPB) Center at Roswell Park Cancer Institute. My primary interest is the diagnosis and treatment of tumors of the liver, pancreas, gallbladder, bile ducts, and stomach. Another major area of interest and experience is the treatment of neuroendocrine tumors, both carcinoid and pancreatic islet cell. I also have expertise in minimally invasive (laparoscopic) surgery to remove tumors of the liver and pancreas. This includes 15 years of experience in performing radiofrequency ablation (RFA) of liver tumors.
My research interests focus on surgical outcomes in liver and pancreas surgery, neuroendocrine tumors, and surgical simulation. I am currently a member of the National Comprehensive Cancer Network (NCCN) Pancreas Cancer Committee; this group continually updates treatment guidelines that help physicians manage patients with pancreatic cancer.
I am a member of American College of Physician Executives, Society of American Gastrointestinal and Endoscopic Surgeons, American College of Surgeons, American Society of Clinical Oncology, American Hepato-Pancreato-Biliary Association and Society of Surgical Oncology. I serve as a peer-reviewer for Annals of Surgical Oncology, the Journal of Surgical Oncology, and World Journal of Surgery. I have authored or co-authored more than 120 journal articles, abstracts, books, and book chapters, and have given numerous presentations around the country concerning gastrointestinal cancers.
Laparoscopic liver and pancreas resection
Radiofrequency ablation (RFA) of liver tumors
Multidisciplinary treatment of neuroendocrine (carcinoid) tumors
Outcomes in liver and pancreas surgery
Education and Training:
MD - University of Maryland, Baltimore, MD
MBA - Yale University, New Haven, CT
University of Cincinnati, Cincinnati, OH
Surgery, American Board of Surgery
Memorial Sloan Kettering Cancer Center, New York, NY
- Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. International journal of radiation oncology, biology, physics 2010; 76(4):1193-1198 .
- Regionalization of pancreatic resection for malignancy in NY State and the effect of hospital volume on perioperative mortality. Annals of surgical oncology 2010; 17(Suppl. 1):S80 .
- Tissue factor is associated with a prothrombotic state in pancreaticobiliary cancer (PBC). Annals of surgical oncology 2010; 17(Suppl. 1):S96 .
- Chemoradiotherapy vs. chemotherapy alone in patients with locally advanced unresectable pancreatic carcinoma: a 10-year experience. International journal of radiation oncology, biology, physics 2010; 78(3 Suppl. 1):S311-S312 .
- Pancreatic adenocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 8(9):972-1017 .
- Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. International journal of radiation oncology, biology, physics 2010; 78(3 Suppl. 1):S298 .
- Change in renal function after chemoradiotherapy for pancreatic cancer : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #231 .
- Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report. JOP : Journal of the pancreas 2009; 10(5):523-527 .
- High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer research 2009; 29(10):4127-4130 .
- Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British journal of cancer 2009; 100(12):1842-1845 .
- Proinflammatory cytokines increase hepatocellular carcinoma cells thermotolerance: evidence of how local inflammation may negatively impact radiofrequency ablation local control rates. Journal of surgical research 2008; 150(1):118-124 .
- CD24 expression is an independent prognostic marker in cholangiocarcinoma. Journal of gastrointestinal surgery 2007; 11(4):445-451 .
- COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Annals of surgical oncology 2007; 14(2):752-758 .
- Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Annals of surgical oncology 2007; 14(2):833-840 .
- Impact of robotics and laparoscopy on surgical skills: A comparative study. Journal of the American College of Surgeons 2007; 204(1):96-101 .
- A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Annals of surgical oncology 2007; 14(11):3202-3209 .
- Surgical therapy of liver metastases. Seminars in oncology 2007; 34(3):177-185 .
- Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2007; 5(10):998-1033 .
- CD24 expression is an independent prognostic marker in cholangiocarcinoma. Annals of surgical oncology 2007; 14(2 Suppl.):57 .
- Improving Compliance with Guidelines for Venous Thromboembolism (VTE) Prophylaxis Significantly Reduces VTE Events. Blood 2008; 112(11):466 .
- Dose Escalation of Octreotide Acetate for Management of Gastro-entero-pancreatic Neuroendocrine Tumors. American journal of gastroenterology 2009; 104(Suppl. 3):S103 (Abstract #268) .
- Evaluation of phosphatidyl inositol 3-kinase catalytic subunit (PI3KCA) and epidermal growth factor receptor (EGFR) gene mutations in pancreatic adenocarcinoma. Annals of surgical oncology 2008; 15(Suppl. 2):33 .
- Bevacizumab in combination with gemcitabine and capecitabine improves quality of life in patients with advanced pancreatic cancer (APC) - final results of the multicenter phase II study. Annals of oncology 2008; 19(Suppl. 6):67 .
- CD24 expression predicts poor outcome in cholangiocarcinoma. Laboratory investigation 2007; 87(Suppl. 1):1300 .
- Renal function after radiotherapy to the abdomen. International journal of radiation oncology, biology, physics 2008; 72(1 Suppl.):S275 .
- Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15072 .
- Outcomes and Tolerability of Treatment for Locally Advanced Pancreatic Cancer Patients 65 Years or Older. International journal of radiation oncology, biology, physics 2011; 81(2 Suppl.):S336 .
- Single institution experience of chemoradiation with gemcitabine versus capecitabine in borderline resectable and locally advanced pancreatic cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14659 .
- Best Practices in Quality and Safety of Patient Care: Roswell Park Cancer Institute Quality Initiative in Venous Thromboembolism Prophylaxis (VTE) for the Oncology Population. Haematologica 2008; 93(Suppl. 1):0878 .
- Advanced hepatocellular carcinoma (HCC) treated with sunitinib (Su) and transarterial chemoembolization (TACE): Phase II trial final report : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #275 .
- Yttrium-90 microspheres (SIR) verses transarterial chemoembolization (TACE) in the treatment of inoperable metastatic neuroendocrine tumors (NETS) : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #300 .
- Neuroendocrine tumors. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(6):724-764 .